Drug-Eluting Resorbable Scaffold Maintains a 3-Year Patency Advantage Over Angioplasty in Infrapopliteal CLTI
Section Structure
1. Highlights. 2. Clinical Background and Unmet Need. 3. LIFE-BTK Trial Design and Endpoints. 4. Three-Year Efficacy Results. 5. Safety and Limb Outcomes. 6. Predictors of Reintervention and Subgroup Findings. 7. Clinical Interpretation and Expert Commentary. 8. Limitations and Remaining Questions. 9. Conclusion. 10. Funding, Trial Registration, and Citation.
Highlights
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.